血清胃蛋白酶原联合幽门螺旋杆菌IgG抗体检测在胃癌早期诊断中的应用价值
|
摘要
目的探讨血清胃蛋白酶原(PG)联合幽门螺旋杆菌(Hp)IgG抗体检测在胃癌早期诊断中的应用价值。方法选取2016年7月-2017年12月在台州市肿瘤医院住院的萎缩性胃炎患者60例、癌前病变患者52例、胃癌患者46例及健康体检者(对照组)40例为研究对象,采用时间分辨荧光免疫分析法检测血清中PGⅠ和PGⅡ浓度,采用胶体金法检测血清Hp-IgG抗体,并对各组结果进行比较分析。结果 PGⅠ浓度和PGR在胃癌组显著低于癌前病变组,癌前病变组显著低于萎缩性胃炎组(P<0.05),萎缩性胃炎组显著低于对照组(P<0.05);胃癌组血清中的PGⅡ浓度显著高于其他3组(P<0.05);萎缩性胃炎组、癌前病变组和胃癌组Hp-IgG抗体阳性率显著高于对照组(P<0.05);Hp-IgG抗体阳性组PGⅠ浓度和PGR显著低于Hp-IgG抗体阴性组,而PGⅡ浓度显著高于Hp-IgG抗体阴性组(P<0.05)。结论检测血清PGⅠ、PGⅡ及Hp-IgG抗体表达水平有助于胃癌的早期筛查。
Objective To explore the application value of serum pepsinogen(PG) combined with Hp-IgG in the early diagnosis of gastric cancer. Methods A total of 60 patients with atrophic gastritis, 52 patients with precancerous lesions, 46 patients with gastric cancer and 40 healthy controls(control group) were enrolled in Taizhou Tumor Hospital from July 2016 to December 2017. The concentrations of PGⅠ and PGⅡ in serum were detected by time-resolved fluoroimmunoassay(TRFIA), and serum Hp-IgG was detected by colloidal gold method. The results of each group were compared and analyzed. Results The concentrations of PGⅠ and PGR in gastric cancer group were significantly lower than precancerous lesions, which in precancerous lesion group was significantly lower than those in atrophic gastritis group, and which in atrophic gastritis group was significantly lower than those in control group(P<0.05). The serum PGⅡ concentration in gastric cancer group was significantly higher than other three groups(P<0.05). The positive rates of Hp-IgG in atrophic gastritis group, precancerous lesion group and gastric cancer group were significantly higher than that in the control group(P<0.05). PGⅠ concentration and PGR were significantly lower in the Hp-IgG positive group than that in the Hp-IgG negative group, and the PGⅡ concentration was significantly higher than that in the Hp-IgG negative group(P<0.05). Conclusion The levels of PGⅠ, PGⅡ and Hp-IgG are helpful for early screening of gastric cancer.
Objective To explore the application value of serum pepsinogen(PG) combined with Hp-IgG in the early diagnosis of gastric cancer. Methods A total of 60 patients with atrophic gastritis, 52 patients with precancerous lesions, 46 patients with gastric cancer and 40 healthy controls(control group) were enrolled in Taizhou Tumor Hospital from July 2016 to December 2017. The concentrations of PGⅠ and PGⅡ in serum were detected by time-resolved fluoroimmunoassay(TRFIA), and serum Hp-IgG was detected by colloidal gold method. The results of each group were compared and analyzed. Results The concentrations of PGⅠ and PGR in gastric cancer group were significantly lower than precancerous lesions, which in precancerous lesion group was significantly lower than those in atrophic gastritis group, and which in atrophic gastritis group was significantly lower than those in control group(P<0.05). The serum PGⅡ concentration in gastric cancer group was significantly higher than other three groups(P<0.05). The positive rates of Hp-IgG in atrophic gastritis group, precancerous lesion group and gastric cancer group were significantly higher than that in the control group(P<0.05). PGⅠ concentration and PGR were significantly lower in the Hp-IgG positive group than that in the Hp-IgG negative group, and the PGⅡ concentration was significantly higher than that in the Hp-IgG negative group(P<0.05). Conclusion The levels of PGⅠ, PGⅡ and Hp-IgG are helpful for early screening of gastric cancer.
引文
[1] 张华,乐嫣,张艺青,等.联合检测胃蛋白酶原、胃泌素-17 及 CEA、CA19-9 在胃癌诊断中的应用[J].标记免疫分析与临床,2018,25(1):5-7.
[2] 谢庆,陈卫刚,齐翠花,等.胃蛋白酶原联合幽门螺旋杆菌IgG 抗体对胃癌早期诊断的价值[J].胃肠病学和肝病学杂志,2016,25(11):1244-1247.
[3] Yamaguchi Y,Nagata Y,Hiratsuka R,et al.Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels-the ABC method[J].Digestion,2016,93(1):13-18.
[4] Yang AP,Liu J,Lei HY,et al.CA72-4 combined with CEA,CA125 and CA19-9 improves the sensitivity for the early diagnosis of gastric cancer[J].Clin Chim Acta,2014,437(2):183-186.
[5] 徐娟,孙雪飞,陈立新,等.血清胃蛋白酶原用于胃癌及癌前疾病的筛查[J].现代临床医学,2017,43(2):108-109.
[6] 邓娜,宫月华.胃黏膜“血清学活检”与萎缩性胃炎[J].胃肠病学和肝病学杂志,2015,24(2):136-139.
[7] 赵秀明.胃蛋白酶原Ⅰ、Ⅱ和胃泌素-17在不同胃黏膜疾病患者血清中的表达水平及意义[J].医学理论与实践,2018,31(3):422-423.
[8] Sokic Milutinovic A,Alempijevic T,Milosavljevic T.Role of Helicobacter pylori infection in gastric carcinogenesis:current knowledge and future directions[J].World J Gastroenterol,2015,21(41):11654-11672.
[9] 王康康,罗金键,汪秀梅,等.联合检测血清胃蛋白酶原和 MG7抗原在胃癌诊断中的意义[J].中国现代医学杂志,2017,27(7):64-66.
[10] 李晓琴,单文杰,董文福,等.胃蛋白酶原和胃泌素对萎缩性胃炎、胃癌的筛查价值及与幽门螺旋杆菌感染的关系[J].宁夏医科大学学报,2017,39(9):1062-1065.
[11] 褚美芬,叶爱青,吴怡春.血清胃蛋白酶原及幽门螺杆菌抗体在胃癌早期诊断中的意义[J].中国卫生检验杂志,2015,25(23):4063-4065.
[12] 周月红,刘雄昌,吴德明,等.血清胃蛋白酶原和幽门螺旋杆菌IgG 抗体在胃癌患者中的表达及其意义[J].内科,2017,12(1):20-23.
[13] Iguchi M,Kato J,Yoshida T,et al.Serum pepsinogen levels can quantify the risk of development of metachronous gastric cancer after endoscopic resection[J].Int J Cancer,2016,139(5):130-142.
[14] 陈卿奇,羊文芳,吴素江,等.血清胃蛋白酶原及胃泌素-17水平与胃癌的相关性研究[J].重庆医学,2016,45(35):4938-4941.
[15] Liu KSH,Wong IOL,Leung WK.Helicobacter pylori associated gastric intestinal metaplasia:Treatment and surveillance[J].World J Gastroenterol,2016,22(3):1311-1320.
[16] Eybpoosh S,Talebkhan Y,Saberi S,et al.Age-specific gastric cancer risk indicated by the combination of Helicobacter pylori sero-status and serum pepsinogen levels[J].Iran Biomed J,2015,19(3):133-142.
[17] Kitamura Y,Yoshihara M,Ito M,et al.Diagnosis of Helicobacter pylori-induced gastritis by serum pepsinogen levels[J].J Gastroenterol Hepatol,2015,30(10):1473-1480.
[18] 章武战,章国东.胃蛋白酶原Ⅰ、Ⅱ与胃幽门螺杆菌( Hp) 检测的相关性[J].中国卫生检验杂志,2015,25(14):2445-2448.
[2] 谢庆,陈卫刚,齐翠花,等.胃蛋白酶原联合幽门螺旋杆菌IgG 抗体对胃癌早期诊断的价值[J].胃肠病学和肝病学杂志,2016,25(11):1244-1247.
[3] Yamaguchi Y,Nagata Y,Hiratsuka R,et al.Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels-the ABC method[J].Digestion,2016,93(1):13-18.
[4] Yang AP,Liu J,Lei HY,et al.CA72-4 combined with CEA,CA125 and CA19-9 improves the sensitivity for the early diagnosis of gastric cancer[J].Clin Chim Acta,2014,437(2):183-186.
[5] 徐娟,孙雪飞,陈立新,等.血清胃蛋白酶原用于胃癌及癌前疾病的筛查[J].现代临床医学,2017,43(2):108-109.
[6] 邓娜,宫月华.胃黏膜“血清学活检”与萎缩性胃炎[J].胃肠病学和肝病学杂志,2015,24(2):136-139.
[7] 赵秀明.胃蛋白酶原Ⅰ、Ⅱ和胃泌素-17在不同胃黏膜疾病患者血清中的表达水平及意义[J].医学理论与实践,2018,31(3):422-423.
[8] Sokic Milutinovic A,Alempijevic T,Milosavljevic T.Role of Helicobacter pylori infection in gastric carcinogenesis:current knowledge and future directions[J].World J Gastroenterol,2015,21(41):11654-11672.
[9] 王康康,罗金键,汪秀梅,等.联合检测血清胃蛋白酶原和 MG7抗原在胃癌诊断中的意义[J].中国现代医学杂志,2017,27(7):64-66.
[10] 李晓琴,单文杰,董文福,等.胃蛋白酶原和胃泌素对萎缩性胃炎、胃癌的筛查价值及与幽门螺旋杆菌感染的关系[J].宁夏医科大学学报,2017,39(9):1062-1065.
[11] 褚美芬,叶爱青,吴怡春.血清胃蛋白酶原及幽门螺杆菌抗体在胃癌早期诊断中的意义[J].中国卫生检验杂志,2015,25(23):4063-4065.
[12] 周月红,刘雄昌,吴德明,等.血清胃蛋白酶原和幽门螺旋杆菌IgG 抗体在胃癌患者中的表达及其意义[J].内科,2017,12(1):20-23.
[13] Iguchi M,Kato J,Yoshida T,et al.Serum pepsinogen levels can quantify the risk of development of metachronous gastric cancer after endoscopic resection[J].Int J Cancer,2016,139(5):130-142.
[14] 陈卿奇,羊文芳,吴素江,等.血清胃蛋白酶原及胃泌素-17水平与胃癌的相关性研究[J].重庆医学,2016,45(35):4938-4941.
[15] Liu KSH,Wong IOL,Leung WK.Helicobacter pylori associated gastric intestinal metaplasia:Treatment and surveillance[J].World J Gastroenterol,2016,22(3):1311-1320.
[16] Eybpoosh S,Talebkhan Y,Saberi S,et al.Age-specific gastric cancer risk indicated by the combination of Helicobacter pylori sero-status and serum pepsinogen levels[J].Iran Biomed J,2015,19(3):133-142.
[17] Kitamura Y,Yoshihara M,Ito M,et al.Diagnosis of Helicobacter pylori-induced gastritis by serum pepsinogen levels[J].J Gastroenterol Hepatol,2015,30(10):1473-1480.
[18] 章武战,章国东.胃蛋白酶原Ⅰ、Ⅱ与胃幽门螺杆菌( Hp) 检测的相关性[J].中国卫生检验杂志,2015,25(14):2445-2448.